CEO James Cacioppo Adds $492K in Jushi Stock Over Two Days
JUSH sits 50% above its 52-week low of $0.34.
Summary
CEO James Cacioppo purchased 994,000 shares of Jushi Holdings for $492,000 on the open market over two days, increasing his indirect holdings through One East Partners L.P.
Key Events · Ownership and Investor Activity · JUSH
-
CEO Buys $492K in Open Market
James Cacioppo acquired 994,000 shares at $0.49-$0.50 per share across August 26-27, 2026, totaling $492,000.
-
Two-Day Accumulation
The purchases follow a $342K buy disclosed on August 26, bringing total recent open-market buying by the CEO to approximately $492K.
-
Indirect Ownership via One East Partners
Shares were purchased through One East Partners L.P., where Cacioppo is a limited partner and managing partner of the investment manager.
-
Post-Transaction Holdings
Cacioppo's indirect holdings in One East Partners L.P. increased to 4,403,462 shares following the transactions.
Analysis · JUSH · Life Sciences
CEO James Cacioppo bought 994,000 shares of Jushi Holdings on the open market across August 26-27 at $0.49-$0.50 per share, totaling $492,000. The purchases were made through One East Partners L.P., an entity he controls as managing partner of its investment manager. This is real money out of pocket, not an option exercise or tax event, and it comes on top of a $342K purchase disclosed two days earlier — bringing his two-day open-market buying to roughly $492K. For a micro-cap company trading near $0.51, a CEO deploying nearly half a million dollars of his own capital is a meaningful conviction signal.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUSH was trading at $0.51 on OTC in the Life Sciences sector, with a market capitalization of approximately $101.9M. The 52-week trading range was $0.34 to $0.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.